Exhibit 99.1
ORGANOVO ANNOUNCES ADJOURNMENT OF
ANNUAL MEETING OF SHAREHOLDERS DUE TO LACK OF QUORUM
Solana Beach, CA., September 17, 2021Organovo Holdings, Inc. (Nasdaq: ONVO), today announced that the Companys annual meeting of
shareholders, on September 14, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.
A quorum consists of a majority of the shares entitled to vote. There were fewer than a majority of shares entitled to vote present, either in person or by
proxy at this meeting. Approximately 45.6% were properly voted at the time of the annual meeting. The annual meeting of shareholders therefore had no quorum and the meeting was adjourned and will reconvene at 9:00 a.m. (Pacific Time) on Tuesday,
October 5, 2021 to be held virtually at www.virtualshareholdermeeting.com/ONVO2021 to allow additional time for the Companys shareholders to vote on the proposals set forth in the Companys definitive proxy statement
filed with the United States Securities and Exchange Commission (the SEC) on August 5, 2021.
During the current adjournment, the Company
continues to solicit votes from its shareholders with respect to the proposals set forth in the Companys proxy statement. Only shareholders of record, as of the record date, July 19, 2021, are entitled to and are being requested to vote.
Important Information
This material may be deemed
to be solicitation material in respect of the Annual Meeting to be reconvened and held on October 5, 2021. In connection with the Annual Meeting, the Company filed a definitive proxy statement with the SEC on August 5, 2021. BEFORE MAKING
ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The definitive proxy statement was
mailed to shareholders who are entitled to vote at the Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. The Companys proxy statement and any other materials filed by the Company
with the SEC can be obtained free of charge at the SECs website at sec.gov or the Companys website https://ir.organovo.com/financial-information/sec-filings.
About Organovo
Organovo is an early-stage biotechnology
company that is developing and utilizing highly customized 3D human tissues as dynamic models of healthy and diseased human biology for drug development. The companys proprietary technology is being used to build functional 3D human tissues
that mimic key aspects of native human tissue composition, architecture, function and disease. Organovos advances include cell type-specific compartments, prevalent intercellular tight junctions, and the formation of microvascular
structures. Management believes these attributes can enable critical complex, multicellular disease models that can be used to develop clinically effective drugs for selected therapeutic areas.